Autolus Therapeutics plc (FRA:6A3A)
1.350
-0.080 (-5.59%)
Last updated: Oct 23, 2026, 3:49 PM CEST
Autolus Therapeutics Employees
As of December 31, 2025, Autolus Therapeutics had 754 total employees, including 752 full-time and 2 part-time employees. The number of employees increased by 104 or 16.00% compared to the previous year.
Employees
754
Change (1Y)
104
Growth (1Y)
16.00%
Revenue / Employee
€136,456
Profits / Employee
€325,658
Market Cap
366.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 754 | 104 | 16.00% | 752 | 2 |
| Dec 31, 2024 | 650 | 179 | 38.00% | 647 | 3 |
| Dec 31, 2023 | 471 | 67 | 16.58% | 463 | 8 |
| Dec 31, 2022 | 404 | 77 | 23.55% | 399 | 5 |
| Dec 31, 2021 | 327 | -57 | -14.84% | 324 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 178,486 |
| Bayer Aktiengesellschaft | 87,830 |
| Siemens Healthineers AG | 74,300 |
| Merck KGaA | 62,136 |
| MEDICLIN Aktiengesellschaft | 7,048 |
| Evotec SE | 4,461 |
| Stratec SE | 1,383 |
| Eckert & Ziegler SE | 1,105 |
Autolus Therapeutics News
- 21 days ago - Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics management to meet virtually with William Blair - TheFly
- 6 weeks ago - Autolus Therapeutics Registration statement: Registration filing - Filings
- 6 weeks ago - Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders - TheFly
- 6 weeks ago - Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel - TheFly
- 6 weeks ago - Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Autolus Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts